Kong XJ - Search Results

1

Enzyme Activity of Natural Products on Cytochrome P450.

Zuo HL, Huang HY, Lin YC, Cai XX, Kong XJ, Luo DL, Zhou YH, Huang HD. Zuo HL, et al. Among authors: kong xj. Molecules. 2022 Jan 14;27(2):515. doi: 10.3390/molecules27020515. Molecules. 2022. PMID: 35056827 Free PMC article. Review.

2

STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape.

Kong X, Zuo H, Huang HD, Zhang Q, Chen J, He C, Hu Y. Kong X, et al. J Adv Res. 2023 Feb;44:119-133. doi: 10.1016/j.jare.2022.05.006. Epub 2022 May 27. J Adv Res. 2023. PMID: 35636721 Free PMC article. Review.

3

The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.

Zuo HL, Lin YC, Huang HY, Wang X, Tang Y, Hu YJ, Kong XJ, Chen QJ, Zhang YZ, Hong HC, Li J, Hu SY, Huang HD. Zuo HL, et al. Among authors: kong xj. Acta Pharmacol Sin. 2021 Jun;42(6):845-847. doi: 10.1038/s41401-021-00645-0. Epub 2021 Apr 13. Acta Pharmacol Sin. 2021. PMID: 33850275 Free PMC article. No abstract available.

4

The Changing Global Landscape in the Development of Artemisinin-Based Treatments: A Clinical Trial Perspective.

Kong XJ, Liu KM, Zuo HL, Huang HD, Hu YJ. Kong XJ, et al. Am J Chin Med. 2022;50(3):733-748. doi: 10.1142/S0192415X22500306. Epub 2022 Mar 10. Am J Chin Med. 2022. PMID: 35282805 Review.

5

What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review.

Liu K, Zhang X, Hu Y, Chen W, Kong X, Yao P, Cong J, Zuo H, Wang J, Li X, Wei B. Liu K, et al. Front Med (Lausanne). 2022 Jul 1;9:925369. doi: 10.3389/fmed.2022.925369. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35847804 Free PMC article.

6

Dendritic-cell-based technology landscape: Insights from patents and citation networks.

Kong X, Hu Y, Cai Z, Yang F, Zhang Q. Kong X, et al. Hum Vaccin Immunother. 2015;11(3):682-8. doi: 10.1080/21645515.2015.1008857. Hum Vaccin Immunother. 2015. PMID: 25714961 Free PMC article. Review.

7

Global patent landscape of programmed cell death 1: implications of the rapid expansion.

Kong X, Zhang Q, Lai Y, Hu H, Chen X, Hu Y. Kong X, et al. Expert Opin Ther Pat. 2018 Jan;28(1):69-80. doi: 10.1080/13543776.2017.1378349. Epub 2017 Sep 19. Expert Opin Ther Pat. 2018. PMID: 28891360 Review.

8

Delivery of therapeutic small interfering RNA: The current patent-based landscape.

Chen Y, Xiong SH, Li F, Kong XJ, Ouyang DF, Zheng Y, Yu H, Hu YJ. Chen Y, et al. Among authors: kong xj. Mol Ther Nucleic Acids. 2022 Jun 22;29:150-161. doi: 10.1016/j.omtn.2022.06.011. eCollection 2022 Sep 13. Mol Ther Nucleic Acids. 2022. PMID: 35847171 Free PMC article.

9

Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016).

Lai Y, Suo S, Wang R, Kong X, Hu Y, Tang D, Shi H, Chen S, Hu H. Lai Y, et al. Hum Vaccin Immunother. 2018 Apr 3;14(4):847-855. doi: 10.1080/21645515.2017.1420445. Epub 2018 Jan 23. Hum Vaccin Immunother. 2018. PMID: 29293380 Free PMC article.

10

Research and development of antibiotics: insights from patents and citation network.

Zhang M, Kong X, Zheng J, Wan JB, Wang Y, Hu Y, Shao R. Zhang M, et al. Expert Opin Ther Pat. 2016 May;26(5):617-27. doi: 10.1517/13543776.2016.1167877. Epub 2016 Apr 6. Expert Opin Ther Pat. 2016. PMID: 26986226 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters